Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM.
Long GV, et al. Among authors: lo sn.
Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077-5. Online ahead of print.
Nat Med. 2024.
PMID: 38907159